Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer

Cisplatin resistance remains a major problem in the treatment of lung cancer. We have discovered that cisplatin resistant (CR) lung cancer cells, regardless of the signaling pathway status, share the common parameter which is an increase in reactive oxygen species (ROS) and undergo metabolic reprogr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Wangpaichitr, Medhi, Wu, Chunjing, Li, Ying Ying, Nguyen, Dan J.M., Kandemir, Hande, Shah, Sumedh, Chen, Shumei, Feun, Lynn G., Prince, Jeffrey S., Kuo, Macus T., Savaraj, Niramol
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564767/
https://ncbi.nlm.nih.gov/pubmed/28525376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17568
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados